Value of 18F-FDG PET/CT in discrimination between indolent and aggressive non-Hodgkin's lymphoma: A study of 328 patients

被引:5
|
作者
Alobthani, Galal [1 ]
Romanov, Victor [1 ]
Isohashi, Kayako [1 ]
Matsunaga, Keiko [1 ]
Watabe, Tadashi [1 ]
Kato, Hiroki [1 ]
Tatsumi, Mitsuaki [2 ]
Shimosegawa, Eku [1 ]
Hatazawa, Jun [1 ]
机构
[1] Osaka Univ, Grad Sch Med, Dept Nucl Med & Tracer Kinet, 2-2 Yamadaoka, Suita, Osaka, Japan
[2] Osaka Univ Hosp, Dept Radiol, 2-2 Yamadaoka, Suita, Osaka, Japan
来源
HELLENIC JOURNAL OF NUCLEAR MEDICINE | 2018年 / 21卷 / 01期
关键词
F-18-FDG PET/CT; Time of flight (TOF); SUVmax cut-off; Detection rate; Aggressive and indolent non Hodgkin's lymphoma; POSITRON-EMISSION-TOMOGRAPHY; STANDARDIZED UPTAKE VALUE; TIME-OF-FLIGHT; HEALTH-ORGANIZATION CLASSIFICATION; FDG-PET; HISTOLOGIC SUBTYPES; COMPUTED-TOMOGRAPHY; LESION DETECTION; T-CELL; SUV;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: Non-Hodgkin's lymphoma (NHL) cases with inconclusive biopsy findings are not infrequently 18 referred for fluorine-18-uorodeoxyglucose positron emission tomography/computed tomography (F-18-FDG PET/CT). We searched for maximum standardized uptake value (SUVmax) cut-off values that could discriminate between indolent and aggressive NHL in conventional non-time of flight (non-TOF) F-18-FDG PET/CT and TOF F-18-FDG PET/CT. Subjects and Methods: Retrospectively, 328 patients were selected by the following inclusion criteria: biopsy-proven NHL with no more than one histopathological type; new cases with 18 less than 90 days between obtaining biopsy and F-18-FDG PET/CT scanning; recurrent cases with time interval more than six months since the last therapy with no history of transformation; and blood glucose less than 150 mg/dL. Two hundred forty six (246) selected patients were scanned with non-TOF PET/CT, and 82 18 18 patients were scanned with TOF F-18-FDG PET/CT. Results: The SUVmax of NHL tends to be higher in TOF F-18-FDG PET/CT than non-TOF F-18-FDG PET/CT. New aggressive NHL had significantly higher SUVmax than new 18 18 indolent NHL in both, non-TOF F-18-FDG PET/CT (13.6 +/- 7.7g/mL vs. 5.3 +/- 3.4g/mL, P<0.0001) and TOF F-18-FDG PET/CT (20.5 +/- 9.8g/mL vs. 6.6 +/- 4.7g/mL, P<0.0001). A receiver operating characteristic curve analysis for 18 new cases in non-TOF F-18-FDG PET/CT (n=204), demonstrated SUVmax of 10g/mL as the most balanced cutoff between aggressive and indolent NHL, with the area under the curve (AUC) of 86%, specificity of 94%, 18 and sensitivity of 71%. While SUVmax of 13g/mL was the most balanced cut-off for new cases in TOF F-18-FDG PET/CT (n=57), with AUC of 91%, specificity of 95.5%, and sensitivity of 77%. Conclusion: Both SUVmax>10g/mL in non-TOF F-18-FDG PET/CT and > 13g/mL in TOF F-18-FDG PET/CT were highly suggestive of an aggressive nature of NHL, while there was an overlap between indolent and aggressive NHL in the lower SUV max levels.
引用
收藏
页码:7 / 14
页数:8
相关论文
共 50 条
  • [1] Hodgkin's disease and aggressive non-Hodgkin lymphoma: The prognostic value of 18F-FDG PET/CT
    Ficola, U.
    Nico, S.
    Ceraudo, Francesco
    Cistaro, A.
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [2] The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma
    Qiu, Lin
    Chen, Yue
    Wu, Jingbo
    HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2013, 16 (03): : 230 - 236
  • [3] Prognostic Value of Radiomics Signature By Diagnostic 18F-FDG PET/CT Analysis in Aggressive Non-Hodgkin's Lymphoma
    Ferrer Lores, Blanca
    Mayorga-Ruiz, Irene
    Alberich Bayarri, Angel
    Morello-Gonzalez, Daniella
    Pastor-Galan, Irene
    Navarro-Cubells, Blanca
    Serrano, Alicia
    Isabel Teruel, Ana
    Dosda-Munoz, Rosa
    Solano, Carlos
    Marti-Bonmati, Luis
    Jose Terol, Maria
    BLOOD, 2018, 132
  • [4] Diagnostic value of baseline 18F-FDG PET/CT and peripheral blood inflammatory markers for aggressive lymphoma in non-Hodgkin's lymphoma
    Jia, Qichen
    Wang, Aihui
    Liu, Yuang
    Fan, Yishuo
    Zhou, Xiaohong
    Liu, Yupeng
    Wu, Liying
    Ouyang, Xiaohui
    Su, Jiagui
    Shi, Baolong
    Liu, Xiaofei
    NUCLEAR MEDICINE COMMUNICATIONS, 2025, 46 (01) : 60 - 66
  • [5] Prognostic Value of SUV in Interim 18F-FDG PET in Non-Hodgkin's Lymphoma Patients
    Cozar Santiago, M.
    Ferrer Rebolleda, J.
    Vicedo Gonzalez, A.
    Sanz Llorens, R.
    Aguilar Barrios, J.
    Devis Saiz, M.
    Sanchez Jurado, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S376 - S376
  • [6] 18F-FDG PET/CT in primary non-Hodgkin's lymphoma of the sinonasal tract
    Tempescul, Adrian
    Querellou, Solene
    Ianotto, Jean-Christophe
    Boisrame, Sylvie
    Valette, Gerald
    Berthou, Christian
    ANNALS OF HEMATOLOGY, 2010, 89 (06) : 635 - 637
  • [7] 18F-FDG PET/CT in primary non-Hodgkin's lymphoma of the sinonasal tract
    Adrian Tempescul
    Solene Querellou
    Jean-Christophe Ianotto
    Sylvie Boisramé
    Gerald Valette
    Christian Berthou
    Annals of Hematology, 2010, 89 : 635 - 637
  • [8] Prognostic value of semiquantitative analysis of interim 18F-FDG PET/CT in patients with non-Hodgkin's lymphoma.
    Henzlova, Lenka
    Kapitanova, Zuzana
    Koranda, Pavel
    Myslivecek, Miroslav
    Papajik, Tomas
    Buriankova, Eva
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (03)
  • [9] Efficacy of 18F-FDG PET/CT in detection of bone marrow involvement in patients with newly diagnosed indolent Non-Hodgkin's Lymphoma
    Sandoval Moreno, C.
    Garcia Alonso, P.
    Tagliatori Nogueira, M.
    Mena Melgar, C.
    de la Rubia Marcos, M.
    Herrero Munoz, A.
    Paniagua Correa, C.
    Castillejos Rodriguez, L.
    Ortega Valle, A.
    Balsa Breton, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S562 - S562
  • [10] Prognostic Value of Interim Chemotherapy 18F-FDG PET/CT in Pediatric Non-Hodgkin Lymphoma
    Wray, Rick
    Mena, Esther
    Solnes, Lilja
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57